 This penny stock could explode. We're going to go through this stock and why I think this it's a penny stock And I've got to say that Institutions continuously keep buying this stock and holding large amounts of this particular stock We'll go through the information that I've got in this video. We'll get right to it I've got to say I'm not a financial advisor I am a business teacher in my daily life, but I'm by no means an expert on the stock market But let's get right into the information. If you could leave the video like that be fantastic. I do appreciate that Let's get into the information So the top 10 owners of this company that we're talking about today, which is vine Therapeutics v y n e and you can notice here that there's been a lot of institutional buying And you can see here for example black rock They've increased the shares in terms of this plus one point four seven seven million Okay, they have now have a total stake of five point three three percent now the big key factor here as well is that the majority the vast majority of investors big institutional investors tend to be Buying more than they are selling and that tells me that there's a lot of confidence in this stock to do quite Well, one of the key parts of this stock is that they've actually got products that are FDA approved Okay, the are FDA approved. So this isn't one of these stocks where you're waiting for FDA approval And then hopefully it has a run-up. This is a stock that actually already has products that are FDA approved Okay, not say some of the ones that pre FDA approval aren't good There's a many of them that are fantastic that could do really well that are trying to get approval, right? But this one is actually got it Okay So you don't have that sort of worry as to whether they're going to get are they going to get FDA approved or not because they Already have been in some of the products that they actually sell. Okay, so let's go into this information here Don't forget to turn notifications on the video Okay, 10 notifications on the challenge was there because we cover many different penny stocks And if you new to the channel welcome, we do cover a range of stocks here where they do happen to have a good run-up So if you're interested in that do subscribe to the channel 10 on the notification bell and also like the video Let's get right into the information So vine therapeutics a bit more information about them. So who are they? So so V y any therapeutics is working to solve some of today's most difficult Therapeutic challenges with every problem tip we take on our approach is the same question traditional assumptions and find a better solution And it says here with every problem we take on our approach is the same And you can see here that their little slogan there So it seems like a very innovative company in the way that they're looking at things that in terms of very disruptive in terms of finding These different solutions and they're very innovative in that sense Now moving on to some of the products. So what do they what do they sell? So first first of all I've got this product called am seek Okay, and it's basically a tropical firm and it's for the treatment of inflammatory lesions of non-modular moderate to severe acne there So that's for that particular product. Okay, then I've also got this other products called Zilx I Which is the first FDA approved product in this particular area apparently according to their website Okay, and and this is involved in this area So it's it's actually involved in solving a diverse skin condition or treating it a diverse skin condition that most commonly Presents with symptoms such as deep facial redness spider veins and acne like inflammatory areas there So this is one of the other products that it's also actually selling this particular Company so they've got they've got a range of products and as we say one of them actually FDA approved according to their website there And as you can see here There is this timeline of the products that they've developed so far and one that they are currently developing So it says that they're creating innovative dermatological medicines to meet the unmet needs in dermatology And for that it demands differentiated Thinking so you've got am seek which has actually reached the FDA approved area. You've got this Zilx I Which has actually reached the FDA approved area, then there's this one here called FCD 105 firm which is currently at phase 2 It needs to get towards phase 3 and then FDA approved for then to actually obviously commercialize this product But they've already got two products there that are FDA approved So they've got a good track history of actually making sure that their products get FDA approved Which is really good and quite promising right so they know what they're doing in that sense And they say the NDA Approval and launching Q4 2020 so that one's just recently launched So that's just going to start to get more sales over time and obviously that's the first tropical particular Solution for that product there. It's been NDA approval So okay, so brilliant stuff So what is the opportunity? What is a total addressable market? So just to have a look at this here You've got this particular product and what it's saying here that it's got potentially Total addressable market up to 1 billion in sales It's got in terms of it's 73% of patients indicate that they are likely to seek a better solution than their current treatment So this is where this product can come in and say look we've got a better treatment that can help out more There's a lot of total addressable market for this potential products And this is only one of them. This is this this particular one here, right? So there is a huge market which means that there is a lot of potential revenue for this product Okay, okay, so just some of the investor highlights here So it's a commercial stage company focused on large and growing markets in dermatology You've got two commercial products here as you can see and they employ proprietary differentiated MST technology It's got strong intellectual property with latest paying into 2037. Okay additional FCD105 Expanding potential product offering and enhances company position as a skilled leader Scaled leader in dermatology Portfolio synergies for leverageable commercial infrastructure It meaning that they can work together there the products and you know the fact that they've got two products as well Large amount of revenue that could come from those two products there and they come through because isn't the commercialization stage Which is really good for investors experienced management team demonstrating execution capabilities Well capitalized with 77 million in cash as a September 30th and 168 million shares outstanding But for 70 70 million in cash There's a good amount of cash and what they now focus on is commercializing the products Broad investor base with a healthy mix of institutional and retail investors And you can see some of the information here that they've actually announced the executive contract with a major BPM for its novel and the tropical firm here And you know so they've announced a partnership there announced a contract which is really good for potential revenue going into the future Now two points I wanted to pick out on the finances was the facts that the research and development expenses So what they've actually done is they've scaled back their research and development rightfully slow Because they've got two products now that are ready to be commercialized So they're scaling back what it seems to be their research and development and then ramping up what seems to be the commercialization and advertising Right, so that's really interesting in terms of potential revenue growth, right? So looking at this they've researched and development expenses for the three months and in 30th September 2020 worth six point six million representing a decrease of five point eight million as Of set 47 percent compared to twelve point five million from the three months ending 30th of September 2019 so there's a scaling back of that With a now focus on the commercialization Side of it and you see the revenues told sixteen point seven million zero point three million for the nine months ending September 30 of 2020 and they are just starting to commercialize these products So we're going to see a lot of potential revenue in the future as they build their brand presence with these products And they get them out there more Now you can see here the current price is at two dollars fifty five It's it had a massive run up to nearly three dollars It's starting to dip a little bit which is starting to present a potential buying opportunity I do think that this stock could easily go to six seven eight dollars very very Well, I would say in the medium term Okay, but I do think that it's got plant chance to run up the catalyst for this is obviously the revenue that comes in With their new products and if their revenue increases, I think this will have an impact on the share price and Any contracts or partnerships they can build as well So there's a lot of potential catalysts and of course you've got that other products that's still going through the stages But the fact they've got two of them that are ready for commercialization FDA approved this is massive. So this is really good So do consider looking at this stock put this on your radar to potentially do some further research into it I certainly think it looks promising. I'm looking to start a position But it did have a big pop so I'm trying to wait for a bit more of a cheaper price But I do want to get into this stock. It does seem like it could be very good If you found this video useful or informative of anywhere, then do like the video subscribe to the channel If you're new we cover many different penny stocks and other stocks as well And we go through those in some detail So I like the video if you knew and subscribe if you knew but also turn on those Notifications so your face to the queue to a new video. Thanks for watching and I'll see everybody in the next one